Safety, Tolerability and Efficacy of Molnupiravir (EIDD-2801) to Eliminate Infectious Virus Detection in Persons With COVID-19

NCT04405570 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

204

Enrollment

INDUSTRY

Sponsor class

Conditions

SARS-CoV-2 Infection, COVID-19

Interventions

DRUG: Molnupiravir 200 mg
DRUG: Molnupiravir 400 mg
DRUG: Molnupiravir 800 mg
DRUG: Placebo (PBO)

Sponsor

Ridgeback Biotherapeutics, LP

Collaborators

[object Object]